89bio, Inc. sold the stake/assets to Roche Holdings, Inc. as part of a acquisition on not available.
Deal value was 3500000000 (source: Extracted) Sector: Biopharmaceuticals; Location: USA.
On the seller side, not available advised, led by Branden Berns, Evan D'Amico, George Sampas, Karen Spindler, Melanie Neary, Pamela Lawrence Endreny, Ryan Murr, Sean Feller.
Generated by AI, original source from - Data is in progress
Found it useful? Spread the word.
Gibson Dunn advises 89bio on its up to $3.5 billion sale to Roche Holdings | The Sponsor - The Sponsor
